All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
Introducing
Now you can personalise
your Lupus Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lupus Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lupus Hub cannot guarantee the accuracy of translated content. The Lupus Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lupus Hub is an independent medical education platform, supported through a grant from AstraZeneca. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Accurate and practical disease activity measures in the management of systemic lupus erythematosus (SLE) are limited.1 The SLE Disease Activity Score (SLE-DAS) is a recently validated 17-item tool that demonstrates high accuracy and sensitivity in assessing changes to disease activity.2
At the 14th European Lupus Meeting, Jesus presented post hoc analyses of phase II and III trials of anifrolumab to:
Here, we summarize the key findings.
Figure 1. HRQoL comparison between patients in A SDA vs non-SDA1 and B MSDA vs non-MSDA2, according to SLE-DAS, BILAG-2004, and SLEDAI-2K*
BILAG, British Isles Lupus Assessment Group; EQ-5D, EuroQoL-5D; FACIT-F, Functional Assessment of Chronic Illness Therapy – Fatigue; MSDA, Moderate-to-Severe Disease Activity; PtGA, Patient Global Assessment; QoL, quality of life; SDA, Severe Disease Activity; SLEDAI-2K, Systemic Lupus Erythematosus Disease Activity Index 2000; VAS, visual analog scale.
*Data from Jesus, et al.1,2
Key learnings |
|
Subscribe to get the best content related to lupus delivered to your inbox